Home » Case Studies » Value Access and Pricing » P&MA Guidance for Enterin…

P&MA Guidance for Entering Into a Competitive Space

CBPartners completed a global P&MA engagement to analyze the pricing strategy for PRODUCT X entering a crowded ALK+ NSCLC landscape.


Develop a robust list and net pricing strategy for the launch of PRODUCT X, taking into account market-by-market funding mechanisms, clinical value proposition, opportunities for differentiation, and the evolving clinical and access landscape in ALK+ non-small cell lung cancer (NSCLC) .



Critically assess the clinical and market access landscape of ALK+ NSCLC, understanding the sequencing, unmet need, funding mechanisms, etc. for existing products. Engage payer and key opinion leader (KOL) expert stakeholders to identify potential opportunities and challenges for PRODUCT X. Synthesize findings to deliver a comprehensive market-by-market list and net launch pricing strategy and recommend an optimal launch strategy.


  • In-depth interview (IDI) moderator guide and exhibits
  • Primary research findings and insights
  • Detailed pricing recommendations by market
  • Strategic global and local guidance to support pricing and market access

Illustrative Outputs


CBP provided detailed final pricing and market access guidance with risk mitigation strategies outlined at both a global and local level that allowed for speed to access in a highly competitive space.